Esperion Therapeutics has been granted a patent for methods of preparing and using a pharmaceutical material containing 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid to lower LDL-C. The invention includes compositions and methods for treating various diseases. GlobalData’s report on Esperion Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Esperion Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Esperion Therapeutics, NSAID cancer drugs was a key innovation area identified from patents. Esperion Therapeutics's grant share as of April 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.

Patent granted for method of lowering ldl-c using pharmaceutical material

Source: United States Patent and Trademark Office (USPTO). Credit: Esperion Therapeutics Inc

A recently granted patent (Publication Number: US11926584B2) discloses a method for lowering low-density lipoprotein cholesterol (LDL-C) in humans by administering a pharmaceutical material containing a crystalline form of a specific compound (formula V). The crystalline form of the compound is characterized by specific X-ray powder diffraction patterns and melting points, ensuring its purity and effectiveness in reducing LDL-C levels. The pharmaceutical material must contain the compound in high concentrations, exceeding 99.5% by weight, with minimal impurities not exceeding 0.2% by weight.

Furthermore, the method allows for the addition of a second therapeutic agent, ezetimibe, to enhance the cholesterol-lowering effects. The patent emphasizes the importance of the compound's purity and specific characteristics in achieving the desired therapeutic outcomes. By following the outlined method and utilizing the pharmaceutical material containing the crystalline form of the compound, healthcare providers can effectively lower LDL-C levels in patients in need, potentially reducing the risk of cardiovascular diseases associated with high cholesterol levels.

To know more about GlobalData’s detailed insights on Esperion Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies